Fosun’s Gland Acquisition Faces Indian Wall?
Chinese group Fosun’s landmark buyout of Gland Pharma appears less likely to go through in India, at least for now, though some experts claim that the deal has always been a tricky one from the Indian standpoint. Indo-China border tensions are unlikely to make things any easier.
You may also be interested in...
Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.
R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.
After several rounds of deferral, an Indian investment board has approved Fosun’s acquisition of Gland Pharma, clearing the way for the first Chinese mega acquisition in the Indian pharmaceutical space, although the deal is still expected to require the go ahead from a Cabinet committee on economic affairs.